Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drugs
Biotech
Polyrizon pays $3M for license to SciSparc's CB2R agonist
Israeli biotech SciSparc has sold the license for its CB2R agonist to its partner Polyrizon to further develop as a pain therapy.
James Waldron
Aug 19, 2024 5:27am
Levicept's ex-Pfizer drug reduces osteoarthritis pain in ph. 2
Aug 6, 2024 1:00am
Vertex inches closer to acute pain market as FDA accepts VX-548
Apr 18, 2024 10:50am
Latigo raises $135M to catch up to Vertex in chronic pain
Feb 14, 2024 5:00am
Seizure drug mechanism could treat osteoarthritis
Jan 5, 2024 10:22am
Confo hands baton to Lilly for non-opioid pain med in $40M deal
Mar 2, 2023 5:00am
